Actively Recruiting
Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy
Led by Dr. Waseem Ullah · Updated on 2025-09-25
116
Participants Needed
1
Research Sites
38 weeks
Total Duration
On this page
Sponsors
D
Dr. Waseem Ullah
Lead Sponsor
H
Hayatabad Medical Complex
Collaborating Sponsor
AI-Summary
What this Trial Is About
Laryngoscopy and intubation during laparoscopic cholecystectomy often cause sudden increases in heart rate and blood pressure, which can be harmful in some patients. Medications such as labetalol and lignocaine are commonly used to reduce this hemodynamic response. This randomized controlled trial at Hayatabad Medical Complex, Peshawar, will compare intravenous labetalol (0.25 mg/kg) and lignocaine (1.5 mg/kg), administered 3 minutes before laryngoscopy. A total of 116 patients undergoing elective laparoscopic cholecystectomy will be randomly assigned to either drug group. The primary goal is to determine which drug is more effective in keeping heart rate and mean arterial pressure within ±20% of baseline during and after intubation. The study will also record blood pressure trends, intubation details, rescue medications, and adverse events such as bradycardia or hypotension. Results will help guide anesthesiologists in selecting the safer and more effective option to maintain cardiovascular stability during surgery.
CONDITIONS
Official Title
Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- ASA Grade I and II
- Age 18 to 60 years
- Scheduled for elective laparoscopic cholecystectomy
- Both genders
- Provided informed consent
You will not qualify if you...
- Allergy to labetalol or lignocaine
- Taking blood pressure medications for hypertension
- ASA Grade III or higher
- Having cardiovascular, kidney, liver, or endocrine diseases
- Pregnant or breastfeeding
- Body mass index 35 or higher
- Expected difficult airway
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hayatabad Med Complex
Peshawar, Khyber Pakhtunkhwa, Pakistan, 25000
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here